Cayston Review To Focus On Missing Data, Additional Dosing Regimens
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee will wrestle with missing data and whether Gilead's cystic fibrosis drug, Cayston, needs additional studies for new dosing regimens.